Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 4/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.45 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.44 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.43 |
| ▸ | KDM6B | O15054 | 1/20 | 0.42 |
| ▸ | KDM5C | P41229 | 1/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.42 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.42 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.42 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8883897 | 0.90 | KDM4E (0.47) | MAPK1ATMPOLBMAPTKDM4E | |
| SCHEMBL31338972 | 0.90 | MAPK1 (0.41) | MAPK1ATMPOLBMAPTKDM4E | |
| SCHEMBL14720510 | 0.90 | ALDH1A1 (0.42) | MAPK1ATMPOLBMAPTKDM4E | |
| SCHEMBL31338967 | 0.90 | MAPK1 (0.41) | MAPK1ATMPOLBMAPTKDM4E | |
| SCHEMBL31338984 | 0.88 | NNMT (0.42) | MAPK1ATMPOLBMAPTKDM4E | |
| SCHEMBL31338988 | 0.88 | NNMT (0.42) | MAPK1ATMPOLBMAPTKDM4E | |
| SCHEMBL20613721 | 0.88 | ALDH1A1 (0.47) | MAPK1ATMMAPTKDM4EP2RY12 | |
| SCHEMBL24213965 | 0.84 | MAPK1 (0.46) | MAPK1ATMPOLBMAPTKDM4E | |
| SCHEMBL24638456 | 0.84 | NPSR1 (0.41) | MAPK1ATMPOLBMAPTKDM4E | |
| SCHEMBL473919 | 0.84 | ALDH1A1 (0.51) | MAPK1ATMPOLBMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4643949-A2 | NICOTINAMIDE RIPK1 INHIBITORS | AbbVie Inc. (US) | 2025-11-05 | — | — | EP | disclosed |
| US-20240360099-A1 | NICOTINAMIDE RIPK1 INHIBITORS | ABBVIE INC. | 2024-10-31 | — | — | US | disclosed |
| CN-117460722-A | Nicotinamide RIPK1 inhibitors | 艾伯维公司 | 2024-01-26 | — | — | CN | disclosed |
| EP-4301744-A1 | NICOTINAMIDE RIPK1 INHIBITORS | AbbVie Inc. (US) | 2024-01-10 | — | — | EP | disclosed |
| US-11767310-B2 | Nicotinamide RIPK1 inhibitors | ABBVIE INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-11767310-B2 | Nicotinamide RIPK1 inhibitors | ABBVIE INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-11767310-B2 | Nicotinamide RIPK1 inhibitors | ABBVIE INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230127127-A1 | NICOTINAMIDE RIPK1 INHIBITORS | ABBVIE INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230127127-A1 | NICOTINAMIDE RIPK1 INHIBITORS | ABBVIE INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230127127-A1 | NICOTINAMIDE RIPK1 INHIBITORS | ABBVIE INC. | 2023-04-27 | — | — | US | disclosed |
| WO-2021032934-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-02-25 | — | — | WO | disclosed |
| CN-101945870-B | 5-anilinoimidazopyridines and methods of use | GENENTECH INC | 2012-10-03 | — | — | CN | disclosed |
| CN-101945870-A | 5-anilinoimidazopyridines and methods of use | GENENTECH INC | 2011-01-12 | — | — | CN | disclosed |
| EP-2195288-A2 | SMALL MOLECULE BRADYKININ B1 RECEPTOR ANTAGONISTS | Jerini AG (DE) | 2010-06-16 | — | — | EP | disclosed |
| WO-2009036996-A2 | SMALL MOLECULE BRADYKININ B1 RECEPTOR ANTAGONISTS | JERINI AG (DE) | 2009-03-26 | — | — | WO | disclosed |
| US-6169183-B1 | REACTING 2,3-DIHALOPYRIDINE WITH CARBON MONOXIDE AND ALKANOL IN PRESENCE OF WEAK BASE AND COMPLEX OF PALLADIUM WITH SPECIFIED BIS(DIPHENYLPHOSPHINE), WHEREIN REACTION IS STOPPED AS SOON AS MAXIMUM CONCENTRATION OF ESTER IS ACHIEVED | LONZA, LTD. (CH) | 2001-01-02 | — | — | US | disclosed |
| US-6162921-A | Process for preparing pyridinecarboxylic esters | LONZA, LTD (CH) | 2000-12-19 | — | — | US | disclosed |
| US-6022973-A | Process for preparing pyridinecarboxylic esters | LONZA LTD. (CH) | 2000-02-08 | — | — | US | disclosed |
| US-5620996-A | Sulfonamidocarbonyl pyridine-2-carboxesteramides and their pyridine-N-oxide compounds and their use as pharmaceuticals | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-04-15 | — | — | US | disclosed |
| US-5610172-A | Sulfonamidocarbonylpyridine-2-carboxamides and pyridine-n-oxides which are useful as pharmaceuticals | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360099-A1 | NICOTINAMIDE RIPK1 INHIBITORS | RIPK1, RIPK2, RIPK4 | MAPK1 202/4885ATM 4501/4885POLB 2859/4885 |
| US-20230127127-A1 | NICOTINAMIDE RIPK1 INHIBITORS | RIPK1, RIPK2, RIPK4 | MAPK1 202/4885ATM 4501/4885POLB 2859/4885 |
| US-11767310-B2 | Nicotinamide RIPK1 inhibitors | RIPK1, RIPK2, RIPK4 | MAPK1 202/4885ATM 4501/4885POLB 2859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.